Jason Atkinson
Director/Board Member at Multiple Sclerosis Society
Net worth: 43 704 $ as of 2024-04-29
Profile
Jason Atkinson currently works at Multiple Sclerosis Society, as Trustee from 2015.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ISOENERGY LTD.
0.01% | 2024-02-27 | 15,721 ( 0.01% ) | 43 704 $ | 2024-04-29 |
Jason Atkinson active positions
| Companies | Position | Start |
|---|---|---|
Multiple Sclerosis Society
 Multiple Sclerosis Society Miscellaneous Commercial ServicesCommercial Services The Multiple Sclerosis Society is an organization that aims to find treatments for everyone affected by multiple sclerosis. The non-profit company is based in London, UK. The British company offers award-winning publications, factsheets, and booklets through their online shop. The society conducts surveys to shape the future direction of MS research, with the latest survey held in 2022 with over 6,500 participants. The company's current focus is on the STARMS trial, which compares HSCT with other highly effective treatments for relapsing MS. The treatment involves using chemotherapy to remove harmful immune cells and regrow the immune system using the patient's own stem cells. Nick Moberly has been the CEO of the company since 2019. | Director/Board Member | 2014-12-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
Multiple Sclerosis Society
Multiple Sclerosis Society Miscellaneous Commercial ServicesCommercial Services The Multiple Sclerosis Society is an organization that aims to find treatments for everyone affected by multiple sclerosis. The non-profit company is based in London, UK. The British company offers award-winning publications, factsheets, and booklets through their online shop. The society conducts surveys to shape the future direction of MS research, with the latest survey held in 2022 with over 6,500 participants. The company's current focus is on the STARMS trial, which compares HSCT with other highly effective treatments for relapsing MS. The treatment involves using chemotherapy to remove harmful immune cells and regrow the immune system using the patient's own stem cells. Nick Moberly has been the CEO of the company since 2019. | Commercial Services |
- Stock Market
- Insiders
- Jason Atkinson
